ERBB2 and gastric cancer: In summary, for Chinese and US patients with previously treated advanced HER2-negative GC or GEJC—whether in the overall population or the PD-L1 CPS ⩾5 population—the ramucirumab plus paclitaxel regimen lacks cost-effectiveness as first-line switch maintenance therapy compared to continuing oxaliplatin-based chemotherapy.